Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Part of interventional neuroradiology procedures for the treatment of selected cerebral
aneurysms are now based on stenting. To reduce thromboembolic events, dual antiplatelet
therapy (APT) combining aspirin and clopidogrel is proposed with close monitoring, since 1/3
of the patients are low responders due to variation of the biological response to clopidogrel
. Ticagrelor is used by few teams but has never been evaluated in a randomized controlled
trial. It could be an option for APT due to more reproducible response with less
interindividual variability and reduced monitoring. The aim of this study is to demonstrate
the interest of ticagrelor for the dual APT for platelet inhibition, in patients undergoing
neurovascular stenting for cerebral aneurysm.